FindTrial
Sign In

Role of Methylcobalamine in Type 2 Diabetes Mellitus patients

Prevalence of Diabetic Peripheral Neuropathy among Type 2 Diabetes Mellitus patients and impact of high dose of Methylcobalamine in patients with Diabetic Peripheral Neuropathy in Urban Etawah: An interventional Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026074
Enrollment
400
Registered
2020-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications Health Condition 2: E114- Type 2 diabetes mellitus with neurological complications

Interventions

Intervention1: Addition of methylcobalamine: 1000 mg, once a day,orally, 6 months Control Intervention1: not applicable: not applicable

Sponsors

self sponsored intramural
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All known diabetics more than or equal to five years

Exclusion criteria

Exclusion criteria: 1. Patients already on methyl-cobalamine treatment 2. Patients who were severely ill, mentally challenged or unable to communicate 3. Patients with chronic lower back pain, neurological history and clinical examination suggestive of myelopathies 4. Pregnant women and patients taking medication known to impair nerve function. 5. Patients not willing to participate in study

Design outcomes

Primary

MeasureTime frame
1.Decrease in the severity or not increase in the severity of diabetic peripheral neuropathyTimepoint: after 6 month of therapy—

Secondary

MeasureTime frame
impact on nephropathy and retinopathyTimepoint: after 6 month of tgerapy—

Countries

India

Contacts

Public ContactDr Kanchan Soni

UPUMS

dhirajk78sri@yahoo.co.in9027156756

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026